Diakonos Oncology Revenue and Competitors
Estimated Revenue & Valuation
- Diakonos Oncology's estimated annual revenue is currently $2.2M per year.
- Diakonos Oncology's estimated revenue per employee is $201,000
Employee Data
- Diakonos Oncology has 11 Employees.
- Diakonos Oncology grew their employee count by -8% last year.
Diakonos Oncology's People
| Name | Title | Email/Phone |
|---|
Diakonos Oncology Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $32.4M | 161 | 20% | N/A | N/A |
#2 | $16.3M | 81 | 7% | N/A | N/A |
#3 | $18.7M | 93 | 16% | N/A | N/A |
#4 | $62.5M | 0 | N/A | N/A | N/A |
#5 | $12.3M | 61 | 7% | N/A | N/A |
#6 | $3.2M | N/A | $22.2M | N/A | |
#7 | $184.1M | 916 | 38% | $50M | N/A |
#8 | $27.7M | 138 | 8% | N/A | N/A |
#9 | $112.4M | 559 | 8% | N/A | N/A |
#10 | $12.5M | 62 | 11% | N/A | N/A |
What Is Diakonos Oncology?
Diakonos Oncology is pioneering cancer treatment with DOC1021, an FDA Fast Track-designated \double-loaded\ dendritic cell therapy for glioblastoma (GBM) and pancreatic cancer (PDAC). This personalized, autologous therapy has shown exceptional safety and efficacy, achieving an 88% 12-month survival rate in unmethylated GBM Phase I trials, with 38% of patients still alive after 18–29 months. With a Phase II trial launching in Q1 2025 at top GBM centers nationwide, Diakonos is reshaping outcomes for patients with the most challenging cancers.
keywords:N/A
N/A
Total Funding
11
Number of Employees
$2.2M
Revenue (est)
-8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Houston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.4M | 11 | 0% | $3M |
#2 | $1M | 11 | N/A | N/A |
#3 | $1M | 11 | N/A | N/A |
#4 | $1M | 11 | N/A | N/A |
#5 | $1.3M | 11 | N/A | N/A |